IMPACT OF GENETIC POLYMORPHISMS ON COVID-19 EVALUATION AND MANAGEMENT

Differences in the dose-response relationship in patients with COVID-19 make the usual dosing regimen in most patients ineffective in some individuals, who do not experience any beneficial effects or experience adverse events. Genetic polymorphisms are the main factors in drug biotransformation enzymes that influence the pharmacokinetic response. With the advancement of investigations in Pharmacogenetics and Pharmacogenomics, it was possible to study some factors that interfere in the therapeutic response of drugs due to some type of polymorphism, including variations in genes, which alter the expression and / or activity of sites associated with drugs, which may have a reduction or increase in activity or amount of protein. Thus, it is believed that the genetic condition affects the pathogenesis of the disease and / or its appropriate treatment. Therefore, we intend to determine the prevalence of genetic polymorphisms in patients with high suspicion of COVID-19 in a prospective multicenter cohort study. Therefore, we seek to evaluate the influence between the polymorphism of the CYP, Interleukins, NOS3, ECA genes in COVID-19. Therefore, it is intended to study participants with a high suspicion of COVID-19 or who have a confirmed diagnosis. Genetic analysis will be performed after DNA extraction from a biological sample provided by the participant, in which the extracted DNA will be subjected to a qualitative PCR (Polymerase Chain Reaction) or qPCR (quantitative Real-Time PCR) technique. The polymorphism analysis may make use of restriction enzymes, depending on the gene region to be analyzed. The allelic and genotypic frequencies will be estimated, using the program SPSS version 20.0, in which associations with probabilities less than 5% will be considered. As a result, it is expected that the understanding of genetic-based factors will assist in clinical decision-making for patient management, contributing to the therapeutic approach centered on the human host. This knowledge will bring a health innovation, and may help health professionals working in both public and supplementary health, to make decisions in the management of patients with better evidence, and thus reduce the host's exposure to an unnecessary risk. In addition, it is intended, as a result, to contribute to a better understanding of severity markers, prognostic factors for COVID-19 severity and death. it is expected that the understanding of genetic-based factors will assist in clinical decision-making for patient management, contributing to the therapeutic approach centered on the human host. This knowledge will bring a health innovation, and may help health professionals working in both public and supplementary health, to make decisions in the management of patients with better evidence, and thus reduce the host's exposure to an unnecessary risk. In addition, it is intended, as a result, to contribute to a better understanding of severity markers, prognostic factors for COVID-19 severity and death. it is expected that the understanding of genetic-based factors will assist in clinical decision-making for patient management, contributing to the therapeutic approach centered on the human host. This knowledge will bring a health innovation, and may help health professionals working in both public and supplementary health, to make decisions in the management of patients with better evidence, and thus reduce the host's exposure to an unnecessary risk. In addition, it is intended, as a result, to contribute to a better understanding of severity markers, prognostic factors for COVID-19 severity and death. and it can help health professionals working in both public and supplementary health to make decisions in the management of patients with better evidence, and thus reduce the host's exposure to an unnecessary risk. In addition, it is intended, as a result, to contribute to a better understanding of severity markers, prognostic factors for COVID-19 severity and death. and it can help health professionals working in both public and supplementary health to make decisions in the management of patients with better evidence, and thus reduce the host's exposure to an unnecessary risk. In addition, it is intended, as a result, to contribute to a better understanding of severity markers, prognostic factors for COVID-19 severity and death.